Anavex Life Sciences Corporation

NASDAQ:AVXL  
11.29
-0.28 (-2.42%)
5:07:26 PM EDT: $11.38 +0.09 (+0.80%)
Products, Regulatory

Anavex Life Sciences Announces Anavex 2-73 (Blarcamesine) Meets Primary And Secondary Endpoints

Published: 12/15/2020 13:46 GMT
Anavex Life Sciences Corporation (AVXL) - Anavex Life Sciences Announces Anavex 2-73 (blarcamesine) Meets Primary and Secondary Endpoints in Placebo-controlled U.S. Phase 2 Clinical Trial for Treatment of Adult Patients With Rett Syndrome.
Anavex Life Sciences Corp - Efficacy Endpoints Demonstrated Statistically Significant and Clinically Meaningful Reductions in Rett Syndrome Symptoms.
Anavex Life Sciences Corp - Key Milestone Met to Advance Regulatory Approval Pathway for Adult Patients With Rett Syndrome.